Finally, our approach allows us to identify a shift mechanism for dysregulated SOCS1 and SOCS3 drivers, showing opposite coactivation patterns in MS patients compared with the healthy controls (Figure 6). Here, SOCS3 is linked to myeloid sarcoma.